As filed with the Securities and Exchange Commission on November 26, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CLEARMIND MEDICINE INC. (Exact name of registrant as specified in its charter) British Columbia 2834 Not Applicable (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 101 ...

Core Insights - Clearmind Medicine Inc. (NASDAQ:CMND) experienced a 7.09% increase in pre-market trading, reaching a price of $0.1713 after closing at $0.16, which was a decline of 19.4% on the previous day [1][6]. Group 1: Clinical Trial Developments - The company announced that Tel Aviv Sourasky Medical Center (TASMC) has enrolled the first participant in its multinational Phase I/IIa clinical trial of CMND-100 for alcohol use disorder, which has received approval from the U.S. Food and Drug Administration [2]. - TASMC is part of an expanded trial network that includes Yale School of Medicine, Johns Hopkins University School of Medicine, and Hadassah Medical Center for patient screening and enrollment [3]. - The Phase I/IIa trial is designed to assess the pharmacokinetics, safety, tolerability, and initial efficacy of CMND-100, an oral MEAI-based medication that is not hallucinogenic, with the first cohort's top-line results indicating no significant adverse events [5]. Group 2: Executive Commentary and Stock Performance - Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, stated that the recruitment of the first patient at TASMC is a significant step that accelerates the global trial [6]. - The company's stock has seen a substantial decline of 88.97% year-to-date, with a 52-week price range of $0.15 to $2.18 and a market capitalization of $5.26 million [6].

Core Insights - Clearmind Medicine Inc. has commenced patient enrollment for its Phase I/IIa clinical trial of CMND-100 for Alcohol Use Disorder (AUD) at Tel Aviv Sourasky Medical Center, marking a significant milestone in the global study [1][2][4] - The trial aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100, a non-hallucinogenic, oral MEAI-based compound, with initial results indicating excellent safety and adherence [3][4] - Clearmind's intellectual property portfolio includes nineteen patent families with 31 granted patents, and the company plans to pursue additional patents to enhance its portfolio [5] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics to address under-treated health issues, particularly AUD [1][4] - The company is committed to researching and commercializing psychedelic-based compounds as regulated medicines, foods, or supplements [4] Clinical Trial Details - The Phase I/IIa trial is being conducted at multiple prestigious sites, including Yale School of Medicine and Johns Hopkins University, in addition to TASMC [2] - The first completed cohort of the trial has shown no serious adverse events, indicating a positive safety profile for CMND-100 [3]

Core Insights - Clearmind Medicine Inc. has received a positive recommendation from its independent Data and Safety Monitoring Board (DSMB) to continue its Phase I/IIa clinical trial for CMND-100, a non-hallucinogenic neuroplastogen aimed at treating Alcohol Use Disorder (AUD) [1][2][3] Group 1: Clinical Trial Details - The ongoing multinational, multi-center trial is assessing the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of CMND-100 in reducing alcohol cravings and consumption among individuals with moderate to severe AUD [2] - The DSMB's review highlighted a favorable safety profile with no serious adverse events reported and general good tolerability across all participants [6] Group 2: Company Statements and Future Outlook - The CEO of Clearmind expressed confidence in CMND-100's safety and therapeutic potential, indicating that the positive interim data positions the company to accelerate enrollment in the trial [3] - The DSMB was established in 2023 to ensure patient safety and data integrity throughout the trial, reflecting the company's commitment to ethical clinical development [3] Group 3: Company Background and Intellectual Property - Clearmind is focused on developing novel psychedelic-derived therapeutics to address significant health issues, including AUD, with the goal of commercializing these compounds as regulated medicines [4] - The company holds an intellectual property portfolio consisting of nineteen patent families, including 31 granted patents, and plans to seek additional patents as warranted [5]

Core Viewpoint - SciSparc Ltd. has announced an advancement in its collaboration with NeuroThera Labs Inc. by filing a patent application for a novel combination therapy targeting depression, which involves 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines like Palmitoylethanolamide (PEA) [1][2] Group 1: Collaboration and Patent Filing - The patent application is a result of the ongoing collaboration between Neurothera and Clearmind Medicine Inc., focusing on a therapy for depression using MEAI and PEA [2][3] - This new filing expands the joint intellectual property portfolio, with a total of 13 patents filed through the collaboration, addressing various conditions including alcohol use disorder, cocaine addiction, obesity, and depression [3] Group 2: Market Context and Impact - According to the World Health Organization, approximately 332 million people globally suffer from major depressive disorder, representing about 5.7% of adults, with higher prevalence in women (6.9%) compared to men (4.6%) [2] - Depression remains one of the leading causes of disability worldwide, significantly contributing to the global burden of disease [2] Group 3: Company Overview - SciSparc Ltd. focuses on clinical-stage pharmaceutical developments through its majority-owned subsidiary Neurothera Labs Inc., which is engaged in developing cannabinoid-based therapeutics [4] - The company is involved in various drug development programs targeting conditions such as Tourette syndrome, Alzheimer's disease, and autism spectrum disorder [4][5]

Core Insights - Clearmind Medicine Inc. has initiated its FDA-approved Phase I/IIa clinical trial for CMND-100 at Hadassah Medical Center, expanding the trial's reach and emphasizing the potential of this non-hallucinogenic MEAI-based oral drug candidate for treating Alcohol Use Disorder (AUD) [1][2] Group 1: Clinical Trial Details - The multinational study aims to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of CMND-100 in reducing alcohol cravings and consumption among individuals with moderate to severe AUD [2] - Hadassah Medical Center was added as a clinical site for the ongoing trial, which was activated swiftly following final approval earlier in the month [2] Group 2: Early Findings - Top-line data from the first cohort of the clinical trial indicated a favorable safety profile, with no serious adverse events reported and high adherence to the dosing regimen [3] - These early findings support the ongoing evaluation of CMND-100 as a potential breakthrough therapy for AUD, a condition affecting millions globally [3] Group 3: Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel psychedelic-derived therapeutics to address under-treated health issues, including AUD [4] - The company's intellectual portfolio includes nineteen patent families with 31 granted patents, and it plans to seek additional patents as warranted [5]

Core Insights - Clearmind Medicine Inc. has initiated its FDA-approved Phase I/IIa clinical trial for CMND-100 at Hadassah Medical Center, expanding the trial's reach and emphasizing the potential of this non-hallucinogenic MEAI-based oral drug candidate for treating Alcohol Use Disorder (AUD) [1][2] Group 1: Clinical Trial Details - The multinational study aims to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of CMND-100 in reducing alcohol cravings and consumption among individuals with moderate to severe AUD [2] - Hadassah Medical Center was added as a clinical site following final approval earlier in November 2025, indicating swift activation and commitment to the trial [2] Group 2: Early Findings - Top-line data from the first cohort of the clinical trial showed a favorable safety profile with no serious adverse events reported, indicating that the treatment was well-tolerated among participants [3] - High adherence to the dosing regimen and protocol requirements was observed, supporting the feasibility and patient acceptability of CMND-100 in a clinical setting [3] Group 3: Company Overview - Clearmind is focused on the discovery and development of novel psychedelic-derived therapeutics to address widespread health issues, including AUD [4] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as warranted [5]

Core Insights - Neurothera Labs Inc. announced that Clearmind Medicine Inc. has filed an Israeli patent application for a combination therapy targeting depression, utilizing 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines like Palmitoylethanolamide (PEA) [1][2] - The collaboration between Neurothera and Clearmind aims to address the significant global issue of major depressive disorder, which affects over 280 million people and is a leading cause of disability [2] Company Overview - Neurothera Labs Inc. is a clinical-stage biotech company focused on developing innovative therapeutics for central nervous system disorders and other underserved health conditions through collaborations [4] Intellectual Property Development - The recent patent application expands the joint intellectual property portfolio, which now includes 13 patents related to MEAI and N-Acylethanolamines for various conditions, including depression, alcohol use disorder, cocaine addiction, and obesity [3]

Core Insights - Clearmind Medicine Inc. announced positive top-line results from its Phase I/IIa clinical trial for CMND-100, a non-hallucinogenic oral drug candidate aimed at treating Alcohol Use Disorder (AUD) [1][2] - The trial demonstrated a favorable safety profile with no serious adverse events and high treatment adherence among participants, indicating the potential for CMND-100 as a breakthrough therapy for AUD [2][4] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics to address under-treated health issues, particularly AUD [5] - The company holds a robust intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [5] Clinical Trial Details - The first cohort of the trial included six patients, treated at prestigious institutions such as Johns Hopkins University and Yale University, under an FDA-approved protocol [3] - The trial is designed to assess the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of CMND-100 in individuals with heavy binge drinking or AUD [3] Executive Commentary - The CEO of Clearmind expressed enthusiasm regarding the initial results, highlighting the encouraging safety profile and treatment observance, which support the company's goal of pioneering therapies for addiction [4]

Core Insights - Clearmind Medicine Inc. has filed a patent application in Israel for a combination therapy targeting depression, utilizing 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines like Palmitoylethanolamide (PEA) [1][2] - The collaboration with Neurothera Labs Inc. aims to address the significant global issue of major depressive disorder, which affects over 280 million people and is a leading cause of disability [2] - The CEO of Clearmind emphasized the importance of this patent application as a milestone in developing innovative treatments for mental health conditions, highlighting the lag in treatment innovation for depression [3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address under-treated health issues, including alcohol use disorder [4] - The company has an extensive intellectual property portfolio, currently consisting of 19 patent families and 31 granted patents, with plans to seek additional patents as warranted [5] Research and Development - The new patent filing expands Clearmind's intellectual property related to MEAI and N-Acylethanolamines, targeting various conditions such as alcohol use disorder, cocaine addiction, obesity, and depression [3] - Preclinical data supports the efficacy of MEAI in reducing addictive behaviors while maintaining normal reward pathways [3]